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n	 INTRODUCTION
Pulmonary arterial hypertension (PAH) is an important vascular disease, po-
tentially lethal. It’s defined as the eleva-
tion of median pulmonary arterial pressure 
(mPAP) above 25 mmHg with a pulmonary 
capillary wedge pressure <15 mmHg at the 
right hearth catheterization (1). According 
to the recent classification of Dana Point 
2008, there are many forms of PAH. In 
particular we distinguish idiopathic PAH 
(iPAH) and PAH associated with connec-
tive tissue diseases (2) whereas this vas-
cular disease is a serious complication of 
systemic sclerosis (SSc) (3). The patho-
genesis of PAH is still unknown, but there 
are many evidences suggesting a role for 
inflammation in the vascular remodelling 
of the precapillary pulmonary arteries. In 
particular cytokines and chemokines are 
involved in the endothelial dysfunction, in 
the hypertrophy and hyperplasia of pulmo-
nary artery smooth muscle cells (PASMCs) 
and in the neointima formation (4). Macro-
phage migration inhibitory factor (MIF) is 
a pleiotropic cytokine with chemokine-like 
functions. It has an isomerase enzymatic 
activity that contributes to chronic inflam-
mation (5). It also acts as endocrine mol-
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Pulmonary arterial hypertension (PAH) can be idiopathic or secondary to autoimmune diseases, and it repre-
sents one of the most threatening complications of systemic sclerosis (SSc). Macrophage migration inhibi-
tory factor (MIF) is a pleiotropic cytokine with proinflammatory functions that appears to be involved in the 
pathogenesis of hypoxia-induced PH. In SSc patients, high serum levels of MIF have been associated with the 
development of ulcers and PAH. Stem cell growth factor b (SCGF b) is a human growth factor that, together 
with MIF, is involved in the pathogenesis of chronic spinal cord injury. The aim of our study was to measure 
serum levels of MIF in patients with idiopathic and SSc-associated PAH.
We enrolled 13 patients with idiopathic PAH and 15 with SSc-associated PAH. We also selected 14 SSc patients 
without PAH and 12 normal healthy controls, matched for sex and age. PAH was confirmed by right hearth 
catheterism (mPAP>25 mmHg). MIF and SCGF b levels were measured by ELISA.
We found significantly higher circulating levels of MIF and of SCGF b in patients with idiopathic PAH (P=0.03 
and P=0.004) and with PAH secondary to SSc (P=0.018 and P=0.023) compared to SSc patients without PAH. 
Higher levels of MIF were found in those patients with an higher New York Heart Association (NYHA) class 
(P=0.03). 
We can hypothesize that MIF and SCGF b are able to play a role in PAH, both idiopathic or secondary, and in 
the future they may be evaluated as useful biomarkers and prognostic factors for this serious vascular disease.
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ecule and as chaperon-like protein. MIF is 
expressed in a wide variety of cells in par-
ticular in immune system cells, epithelial 
and endothelial cells, SMC and endocrine 
system cells (6). MIF has many functions: 
it works against the immunosuppres-
sive action of glucocorticoids, activates 
CXCR2 and CXCR4 dependent chemo-
tactic responses, increases the production 
of pro-inflammatory cytokines such as 
tumour necrosis factor-a and inhibits the 
activation-induced apoptosis (7). It is also 
involved in the pathogenesis of atheroscle-
rosis (8) and of many autoimmune diseases 
(6) and it plays a key, but controversial, 
role in wound repair (9). In SSc, it seems 
to contribute to sclerodermic vasculopathy. 
In fact MIF serum and tissue levels were 
significantly increased in SSc patients in 
comparison to healthy controls. In particu-
lar patients with PAH and recurrent digi-
tal ulcers showed higher MIF levels than 
patients without these manifestations (10, 
11). 
Besides, a particular genetic polymor-
phism, MIF-173 promoter polymorphism, 
is associated with the diffuse form of SSc 
(12, 13). Recent evidences show a role 
of MIF in the pathogenesis of hypoxia-
induced PH with higher levels in patients 
with idiopathic and with interstitial lung 
disease associated PH respect to healthy 
controls (14). MIF may induce the prolif-
eration of PASMCs and may enhance the 
vasoconstriction of pulmonary arteries 
in murine models and in human in vitro 
models (15, 16). Because of its role of me-
diator of pathogenic mechanisms in many 
systemic and organ-specific autoimmune 
diseases, neutralizing the action of endog-
enous MIF with monoclonal antibodies or 
small chemical inhibitors of its tautomer-
ase activity, such as ISO-1, may be effec-
tive in the control of several models of au-
toimmune diseases (6, 7). 
Stem cell growth factor (SCGF) is a hu-
man growth factor for hematopoietic pro-
genitor cells, which belongs to the C-type 
lectin superfamily (17). There are two iso-
forms (a and b) and SCGF b exhibits a 
burst-promoting activity and granulocyte/
macrophage colony stimulating activity 
on erythroid and granulocyte/macrophage 
progenitor cells (18). It seems to have a 
prognostic role in Chagas’ disease and id-
iopathic dilated cardiomyopathy (19). Its 
serum levels seem to increase following 
stem cell transplantation (20), and together 
with MIF, it is involved in the pathogenesis 
of chronic spinal cord injury (21). No data 
are actually available concerning its role in 
SSc and in PAH.
n	 MATERIALS AND METHODS
Objectives
We dosed MIF and SCGF b serum levels in 
patients affected by PAH, both idiopathic 
and secondary to SSc, to determine their 
potential role in the development of this 
important vascular disease and any poten-
tial difference between the two forms of 
PAH.
Methods
We enrolled 13 consecutive patients af-
fected by iPAH who had been referred to 
the Pulmonary Hypertension Center of our 
Hospital and 15 consecutive patients re-
ferred to our Rheumatology Unit affected 
by the SSc-associated form of PAH. As 
controls we enrolled 14 patients affected 
by SSc without PAH and 12 normal healthy 
controls (NHC) sex and age matched. 
SSc patients were classified according the 
American College of Rheumatology (ACR) 
classification criteria of 1980 (22) and the 
classification was confirmed with the new 
ACR/European League Against Rheuma-
tism (EULAR) Criteria of 2013 (23). The 
diagnosis of PAH was confirmed by right 
hearth catheterization and it was defined 
as a precapillary pulmonary hypertension 
(mPAP >25 mmHg, pulmonary wedge 
pressure <15 mmHg) (1). All patients un-
derwent to clinical and laboratory evalua-
tion, including the assessment of the New 
York Heart Association (NYHA) functional 
class. SSc patients organ involvement was 
defined as previously described (24): lung 
= bibasilar pulmonary fibrosis on chest ra-
diography; isolated PH = clinical evidence 
of PH and increased systolic pulmonary ar-
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terial pressure (>35 mmHg), indirectly as-
sessed by echocardiography, in the absence 
of severe pulmonary interstitial fibrosis; oe-
sophagus = hypomotility shown by barium 
radiography; joint = inflammatory polyar-
thralgias or arthritis; heart = pericarditis, 
congestive heart failure, or arrhythmias 
requiring treatment. High-resolution com-
puted tomography was performed in each 
case showing negative x-ray and the diag-
nosis of pulmonary fibrosis was done by a 
radiologist, blinded reading, basing on the 
presence either of bilateral basilar reticulo-
nodular changes on x-ray or of ground glass 
appearance of the lung parenchyma on 
HRTC. The cutaneous evaluation included: 
presence/absence of Raynaud’s phenom-
enon, modified Rodnan skin score (25), 
presence/absence of digital ulcers, defined 
as a loss of epithelialization and tissues in-
volving the epidermis, the dermis and the 
subcutaneous tissue, teleangiectasia, calci-
nosis, defined as deposits of calcium in soft 
tissues eye visible or confirmed by x-ray 
(26). All patients underwent a nailfold vid-
eocapillaroscopy as previously described 
(27). Antinuclear antibodies including 
anti-centromere antibodies were detected 
by indirect immunofluorescence using 
HEp-2 cell line as substrate (Bio-Rad Lab., 
Hercules, CA, USA). Antibodies against 
topoisomerase I (anti-Scl70) were mea-
sured using enzyme-linked immunosorbent 
assays (ELISA) (Diamedix, Miami, FL, 
USA). Serum sample was obtained from 
all patients and sera were stored at -20°C. 
Levels of MIF and SCGF b were detected 
by enzyme-linked immunoassay (Bio-Rad 
Lab.). Assays were performed following the 
manufacturer’s instructions. 
Statistical analysis
The Mann-Whitney U test was used for 
comparison of groups. For correlation 
analysis, Spearman’s rank correlation test 
was employed. P values≤0.05 were consid-
ered significant. 
n	 RESULTS
All SSc patients were female, 15 with PAH 
(mean age 67 yrs, range 50-75; mean dis-
ease duration 230 months; range 4-696) 
and 14 without PAH (mean age 62.5 yrs, 
range 47-79; mean disease duration 154.6 
months, range 84-502). Among those pa-
tients with PAH, 10 had the limited form of 
SSc and 5 had the diffuse form, the mean 
mRSS was 13 (range 4-30), 2 had digital 
ulcers, 5 were anti-centromere positive and 
1 anti-Scl70 positive, while in the group 
without PAH, 12 had the limited form and 
2 had the diffuse form, the mean mRSS 
was 11 (range 4-24), 4 had digital ulcers, 
10 were anti-centromere positive and 4 
anti-Scl70 positive (Tab. I). The 13 patients 
with iPAH were 9 female and 4 male (mean 
age =55.7 yrs; mean disease duration = 
5.48 yrs) and the 12 NHC were sex and age 
matched. 
We found significantly higher circulat-
ing levels of MIF and of SCGF b in pa-
tients with idiopathic PAH (MIF median 
270 pg/mL vs 175 pg/mL, P=0.03; SCGF 
b median 18,845 pg/mL vs 12,054 pg/
Table I - Main clinical-demographic and laboratory features of systemic sclerosis (SSc) patients, with and 
without pulmonary arterial hypertension (PAH).
SSc patients without PAH (n=14) Patients with SSc-associated 
PAH (n=15)
P
Sex (F) 14 15 n.s.
Mean age (range) 62.5 yrs (47-79) 67 yrs (50-75) n.s.
Mean disease duration (range) 154.6 months (84-502) 230 months (4-696) n.s.
Form (L/D) 12/2 10/5 n.s.
Mean mRSS (range) 11 (4-24) 13 (4-30) n.s.
Digital ulcers (n. pt.) 4 (28.5%) 2 (13%) n.s.
Anti-centromere+ve 10 (71%) 5 (33%) n.s.
Anti-topoisomerase1+ve 4 (29%) 1 (7%) n.s.
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mL, P=0.004) and SSc-associated PAH 
(MIF median 333 pg/mL vs 175 pg/mL, 
P=0.018; SCGF b median 17,804 pg/mL 
vs 12,054 pg/mL, P=0.023) compared to 
SSc patients without PAH (Tab. II and III; 
Fig. 1 and 2). We found higher mean lev-
els of MIF and SCGF b in SSc patients, 
in particular in those with PAH, and in 
patients with iPAH compared to normal 
control but the differences were not sta-
Table III - Macrophage migration inhibitory factor 
(MIF) and stem cell growth factor (SCGF) b serum 
levels (pg/mL) in patients with systemic sclerosis 
(SSc)-associated pulmonary arterial hypertension 
(PAH) and in SSc patients without PAH (SSc con-
trols) (median±standard deviation).
SSc-associated 
PAH
SSc controls P
MIF 333±520 175±68.68 0.018
SCGF b 17,804±8033.2 12,054±3448.5 0.023
Table II - Macrophage migration inhibitory factor 
(MIF) and stem cell growth factor (SCGF) b serum 
levels (pg/mL) in patients with idiopathic pulmo-
nary arterial hypertension (iPAH) and in systemic 
sclerosis (SSc) patients without PAH (SSc controls) 
(median±standard deviation).
iPAH SSc controls P
MIF 270±636.2 175±68.68 0.03
SCGF b 18,845±5819.7 12,054±3448.5 0.004
Figure 1 - Macrophage migration inhibitory 
factor (MIF) serum levels (pg/mL) in patients 
with idiopathic pulmonary arterial hyperten-
sion (iPAH) and systemic sclerosis (SSc)-as-
sociated PAH (P=0.03 and P=0.018).
Figure 2 - Stem cell growth factor (SCGF) 
b serum levels (pg/mL) in patients with idio-
pathic pulmonary arterial hypertension (iPAH) 
and systemic sclerosis (SSc)-associated PAH 
(P=0.04 and P=0.023).
Figure 3 - Macrophage migration inhibitory 
factor (MIF) serum levels (pg/mL) in patients 
with the New York Heart Association (NYHA) 
functional classes 3-4 and NYHA functional 
classes 1-2 (P=0.03).
tistically significant. We didn’t find any 
significant difference between the two 
forms of PAH and regarding other vas-
cular manifestations such as digital ul-
cers and nailfold capillaroscopy features. 
Besides we found a significant increase 
of MIF levels in patients with an higher 
NYHA functional classes (class NYHA 
3-4 vs class NYHA 1-2) (median 380.69 
pg/mL vs 244.58 pg/mL, P=0.03) (Fig. 3). 
We didn’t find any significant correlation 
between MIF and SCGF b and other clini-
cal or laboratory parameters.
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n	 CONCLUSIONS
PAH is an important vascular disease, po-
tentially lethal and it can be associated 
with connective tissue diseases (2). MIF is 
a pleiotropic cytokine and in SSc patients, 
serum levels of MIF are increased com-
pared to healthy controls and have been 
associated with the development of ulcers 
and PAH (11). Moreover, MIF seems to be 
involved in the pathogenesis of hypoxia-
induced PH, showing higher levels in those 
patients with idiopathic PH and with inter-
stitial lung disease-associated PH respect 
to healthy controls (14). SCGF b seems to 
have a prognostic role in Chagas’ disease 
and idiopathic dilated cardiomyopathy (19) 
and together with MIF, is involved in the 
pathogenesis of chronic spinal cord injury 
(21). In our study, we found significantly 
higher levels of MIF and SCGF b in pa-
tients with iPAH and SSc-associated PAH, 
without any significant difference between 
the two forms of PAH. Regarding MIF, 
unlike other studies (11), we didn’t found 
any significant association with the other 
clinical manifestation of SSc vasculopathy, 
such as digital ulcers. In a previous study, 
we found a significant association between 
a more severe capillaroscopic score and 
the presence of PAH (28). Instead, in this 
study, we didn’t find any significant associ-
ation between the serum levels of MIF and 
SCGF b and the nailfold capillaroscopic 
features. Like previous study (10, 11), 
we found higher mean levels of MIF and 
SCGF b in SSc patients, in particular in 
those with PAH, and in patients with iPAH, 
compared to normal control but the dif-
ferences were not statistically significant, 
probably because of the small sample size. 
Thus, the higher serum levels of MIF 
seem, in our cohort of patients, to be spe-
cific of PAH and these data are consistent 
with the recent evidences for a role of MIF 
as a molecular mediator in the pathogen-
esis of PH in murine and human in vitro 
models (15, 16). No data are actually avail-
able regarding the SCGF b involvement in 
PAH and in SSc pathogenesis. SCGF b has 
been studied as a prognostic factor in other 
kinds of cardiovascular diseases (19). 
Thus our study presents for the first time 
an association among this molecule, PAH 
and SSc. Because of the potential lethality 
of PAH, there is a need of sensible diag-
nostic tools to early assess the development 
of this important vascular disease. The next 
step of our research will be to verify the 
real sensibility of these molecules. 
We also found that significantly higher 
serum levels of MIF, but not of SCGF b 
are present in patients with higher NYHA 
functional classes (NYHA 3 and 4) prob-
ably reflecting a more severe vascular dam-
age and, consequently, a more severe type 
of PAH. Thus MIF seems to behave as a 
prognostic marker, to be used for monitor-
ing patients with PAH. Our study confirms 
the association of MIF, a proinflammatory 
cytokine, with PAH and these results are 
consistent with the evidence that suggests 
a role for inflammation in the vascular re-
modelling of the precapillary pulmonary 
arteries, that are among the main features 
of the pathogenetic mechanism of PAH (4). 
To establish the possible role of MIF in 
the pathogenesis of PAH, both idiopathic 
and secondary, may have important conse-
quences in the current therapeutic strategy 
for PAH (1). In fact monoclonal antibod-
ies directed against MIF or small chemical 
inhibitors of its tautomerasic activity, such 
as ISO-1, are already experienced in many 
models of autoimmune diseases (6, 7). 
In conclusions, with our study we can hy-
pothesize a role for MIF and SCGF b as 
biomarkers of PAH and, for MIF in par-
ticular, as a prognostic marker. 
Further studies are needed to identify a 
clear pathogenetic role for these molecules 
in the development of PAH, as well as their 
potential use as therapeutic targets.
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